Abbott Laboratories (ABT) has been the subject of considerable attention after its strong Q1 2025 earnings, receiving applause from Jim Cramer and being touted as an attractive investment for its potential growth and dividends. This was despite its Earnings Per Share (EPS) missing expectations, reflecting a mix of outcomes. ABT's stock rose on these robust earnings, with tariffs concerns easing their impact. A significant $500M investment into US facilities was highlighted as a driving factor. Analyst views are vastly positive, with Citi reaffirming their buy rating and Wells Fargo also recommending a 'buy'. The company affirmed its outlook for FY25 following earnings results. However, its first-quarter sales missed expectations leading a slight dip in stock. MedTech growth and a diversified business contribute to ABT's resilience. Critics note the mismatch between the company's earnings growth and shareholders' returns. ABT anticipates modest earnings growth amid cautious sentiment in the market. Yet, the stock has managed to surpass Q1 earnings expectations, and multiple price targets were increased by RBC Capital, Oppenheimer, and Bernstein.
Abbott Laboratories ABT News Analytics from Wed, 22 Jan 2025 08:00:00 GMT to Sat, 19 Apr 2025 16:10:50 GMT -
Rating 8
- Innovation 5
- Information 9
- Rumor -3
